Bevacizumab nasal spray: Noninvasive treatment of epistaxis in patients with Rendu-Osler disease.
Fiche publication
Date publication
mai 2012
Journal
The Laryngoscope
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DEBRY Christian
Tous les auteurs :
Guldmann R, Dupret A, Nivoix Y, Schultz P, Debry C
Lien Pubmed
Résumé
To evaluate the efficacy and safety of bevacizumab administered at a concentration of 50 mg as an intranasal spray in the treatment of epistaxis in patients suffering from Rendu-Osler disease.
Mots clés
Administration, Intranasal, Aerosols, Angiogenesis Inhibitors, administration & dosage, Antibodies, Monoclonal, Humanized, administration & dosage, Bevacizumab, Dose-Response Relationship, Drug, Epistaxis, drug therapy, Female, Follow-Up Studies, Humans, Male, Middle Aged, Nasal Sprays, Prospective Studies, Quality of Life, Telangiectasia, Hereditary Hemorrhagic, complications, Treatment Outcome, Vascular Endothelial Growth Factor A
Référence
Laryngoscope. 2012 May;122(5):953-5